Clinical Trials Sponsored by Timmune Biotech Inc.

Total 448 results

CEN Biotech
Takeda; BioClinica, Inc.

Completed

Retrospective and Prospective Observational Study of MRI Changes in Bone and Visceral Lesions of Patients With Type 1 Gaucher Disease Treated With VPRIV® (Velaglucerase Alfa) (EIROS)

MRI | Gaucher Disease, Type 1

France
Facet Biotech
PDL BioPharma, Inc.

Terminated

A Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis

Ulcerative Colitis

France, Belgium, United States, Israel, Australia, Germany, Netherlands, Austria, Canada, Czech Republic, Ukraine, Norway, Hungary, Slovakia
Facet Biotech
PDL BioPharma, Inc.

Terminated

Study of Visilizumab Versus Placebo in Subjects With Intravenous Steroid-refractory Ulcerative Colitis Previously Responsive in a Visilizumab Study

Ulcerative Colitis

Belgium, France, United States, Italy, Canada, Czech Republic, Norway, Israel, Austria, Croatia, Australia, Hungary, Ukraine, Netherlands, Germany
Facet Biotech
PDL BioPharma, Inc.

Withdrawn

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis

Intravenous Steroid-Refractory Ulcerative Colitis
Portage Biotech
Tarus Therapeutics, Inc.

Active, not recruiting

TT-10 as a Single Agent in Subjects With Advanced Selected Solid Tumors

Non Small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Renal Cell Cancer | Castrate Resistant Prostate Cancer

United States
NKGen Biotech, Inc.
Affimed GmbH

Terminated

Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing Cancers

Carcinoma, Non-Small-Cell Lung | Colorectal Neoplasms | Squamous Cell Carcinoma of Head and Neck | Advanced Solid Tumor | Metastatic Tumor | Refractory Tumor

United States
Krystal Biotech, Inc.
Stanford University

Withdrawn

The Natural History of Wounds in Patients With Dystrophic Epidermolysis Bullosa (DEB)

Dystrophic Epidermolysis Bullosa | DEB - Dystrophic Epidermolysis Bullosa

United States
Aduro Biotech, Inc.
Incyte Corporation

Terminated

Safety and Efficacy of CRS-207 With Epacadostat in Platinum Resistant Ovarian, Fallopian or Peritoneal Cancer (SEASCAPE)

Platinum-resistant Ovarian Cancer | Platinum-resistant Fallopian Cancer | Platinum-resistant Peritoneal Cancer

United States, Canada
Janssen Biotech, Inc.
Pharmacyclics LLC.

Approved for marketing

An Open Label Treatment Use Protocol for Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma

Relapsed or Refractory Mantle Cell Lymphoma

United States, Brazil, Puerto Rico
Facet Biotech
PDL BioPharma, Inc.

Completed

Visilizumab for Moderate to Severe Inflammatory, Nonstricturing, Nonpenetrating Crohn's Disease

Crohn's Disease

United States
PDL BioPharma, Inc.

Completed

Volociximab in Combination With DTIC in Patients With Metastatic Melanoma Not Previously Treated With Chemotherapy

Melanoma | Metastases

United States
PDL BioPharma, Inc.

Terminated

A Phase 2 Study to Evaluate the Safety, Tolerability, and Activity of Fontolizumab in Subjects With Active Rheumatoid Arthritis

Arthritis, Rheumatoid

United States
Immune Oncology Research Institute
Agenus Inc.

Recruiting

Assessment of the Safety and Efficacy of Balstilimab for the Treatment of Relapsed/Refractory Lymphomas (IMMONC0001)

Lymphoma

Armenia
Immune Cell, Inc.
Weifang People's Hospital

Recruiting

A Clinical Study of CD19 Targeted CAR-T for Patients With CD19+ Lymphoma and Leukemia

B Cell Lymphoma | B Cell Leukemia

China
Immune Cell, Inc.
Weifang People's Hospital

Recruiting

CD30 Targeted CAR-T in Treating CD30-Expressing Lymphomas

Hodgkin Lymphoma | Anaplastic Large Cell Lymphoma

China
Institut Pasteur
Janssen Biotech, Inc.

Recruiting

The Role of IL-23 in Chronic Inflammatory Disease: Exploring the Cellular and Molecular Targets of IL-23 Signaling in Peripheral and Axial Spondyloarthritis (SpA23)

Spondyloarthritis

France
Institut Pasteur
Janssen Biotech, Inc.

Recruiting

Exploration of the Cellular and Molecular Mechanisms in Patients Receiving Biotherapies Targeting the IL-23/IL-17 Axis in Cutaneous Psoriasis (Pso23)

Psoriasis

France
Milestone Pharmaceuticals Inc.
IQVIA Biotech

Completed

Safety Study of Etripamil Nasal Spray for Patients With Paroxysmal Supraventricular Tachycardia. NODE-303

Paroxysmal Supraventricular Tachycardia

United States, Argentina, Brazil, Canada, Colombia
Laboratoires Thea
Axial Biotech, Inc

Withdrawn

Assessment of Patient's Satisfaction Regarding the Handiness of Two Hyaluronic Acid Eye Drops Vials

Assess the Patient Feeling About the Handiness of Two Different Vials Used to Deliver Both, Unpreserved Hyaluronic Eye Drops

Germany
Facet Biotech
PDL BioPharma, Inc.

Completed

Ulcerative Colitis Study: Study of Visilizumab in Patients With Severe Ulcerative Colitis

Severe Ulcerative Colitis

United States
Facet Biotech
PDL BioPharma, Inc.

Completed

Visilizumab for Treatment of Perianal Fistulas in Crohn's Disease

Crohn's Disease

United States
Queen's University
Ortho Biotech, Inc.

Terminated

REPEAT Study - Resistance to ErythroPoietin Effectiveness Algorithm Trial

Kidney Failure, Chronic | Drug Resistance

Canada
PDL BioPharma, Inc.

Completed

Study of Subcutaneous Daclizumab in Patients With Active, Relapsing Forms of Multiple Sclerosis

Multiple Sclerosis

United States, Canada
PDL BioPharma, Inc.

Terminated

An Observational Follow-up Study for Subjects Receiving Salvage Therapy After Previous Treatment in a Visilizumab Study for Intravenous Steroid-Refractory Ulcerative Colitis

Ulcerative Colitis

Belgium, France, United States, Italy, Australia, Czech Republic, Netherlands, Ireland, Norway, Canada, Austria, Germany, Hungary, Ukraine
Edesa Biotech Inc.
JSS Medical Research Inc.

Recruiting

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of EB05 + SOC vs. Placebo + SOC in Adult Hospitalized Patients With COVID-19

COVID-19 | ARDS

United States, Canada
Milestone Pharmaceuticals Inc.
Medpace, Inc.; IQVIA Biotech

Completed

Efficacy and Safety of Etripamil for the Termination of Spontaneous Paroxymal Supraventricular Tachycardia (PSVT). NODE 301 [Part 1 and Part 2 (RAPID Study)]

Paroxysmal Supraventricular Tachycardia

United States, Spain, Canada, Belgium, France, Netherlands, Hungary, Poland, Germany
Edesa Biotech Inc.
JSS Medical Research Inc.

Active, not recruiting

Evaluation of EB01 Cream for the Treatment of Chronic Allergic Contact Dermatitis

Allergic Contact Dermatitis

United States, Canada
PrimeVax Immuno-Oncology Inc.

Not yet recruiting

Arm 1: Lysate Pulsed Dendritic Cells (PV-001-DC) in Patients With Melanoma

Metastatic Melanoma
SOTIO Biotech AG
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors

Hepatocellular Carcinoma | Colorectal Cancer | Ovarian Cancer | Non-Small Cell Lung Cancer | Castration-resistant Prostate Cancer | Cutaneous Squamous Cell Carcinoma

Italy, Spain, France, Belgium, Czechia, United States, Poland, Georgia, Hungary
DualityBio Inc.
BioNTech SE

Recruiting

A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)

Metastatic Breast Cancer

United States, China, Australia
DualityBio Inc.
BioNTech SE

Recruiting

First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors

Advanced Solid Tumor

United States, China, Puerto Rico
OncoC4, Inc.
BioNTech SE

Recruiting

ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors (PRESERVE-003)

Non Small Cell Lung Cancer

United States, Belgium, Canada, France, Germany, Italy, Spain, China, Korea, Republic of, Netherlands, Turkey, United Kingdom, Australia
BioNTech SE
Genentech, Inc.

Recruiting

A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer

Colorectal Cancer Stage II | Colorectal Cancer Stage III

United States, Spain, United Kingdom, Germany, Belgium, Sweden
BioTex, Inc.

Not yet recruiting

Ark Cannulation Trial II (ACT II)

Vascular Access Complication | Dialysis; Complications
BioTex, Inc.

Completed

Laser Interstitial Thermal Therapy Under "Real Time" MRI Guidance for "Minimal Invasive" Treatment of Liver Metastasis

Digestive System Neoplasms | Carcinoma, Hepatocellular | Liver Neoplasms

France
BioTex, Inc.

Completed

MR Guided Laser Interstitial Thermal Therapy for the "Minimal Invasive" Treatment of Brain Metastasis and Primary Brain Tumors

Brain Neoplasms | Brain Cancer | Brain Tumor | Recurrent Brain Tumor

France
Immune Oncology Research Institute
Agenus Inc.

Recruiting

Assessment of the Safety and Efficacy of Balstilimab in Combination With Botensilimab for the Treatment of Non-Small Cell Lung Cancer (IMMONC0008)

Non-small Cell Lung Cancer

Armenia
Mural Oncology, Inc
Immune Oncology Network

Completed

A Study of ALKS 4230 (Nemvaleukin Alfa) With Pembrolizumab in Head and Neck Cancer

Non-cutaneous Squamous Cell Carcinoma of Head and Neck

United States
BioNTech SE
DualityBio Inc.

Not yet recruiting

A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer

Endometrial Cancer
DualityBio Inc.
BioNTech SE

Recruiting

A Study to Compare DB-1303/BNT323 Versus T-DM1 in Breast Cancer

HER2-positive Breast Cancer

China
Genentech, Inc.
BioNTech SE

Recruiting

A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected Pancreatic Ductal Adenocarcinoma (IMCODE003)

Adenocarcinoma, Pancreatic Ductal

United States, Canada, United Kingdom
Genentech, Inc.
BioNTech SE

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran (RO7198457) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Participants With Previously Untreated Advanced Melanoma. (IMCODE001)

Advanced Melanoma

United States, Spain, Belgium, Australia, Germany, United Kingdom
Genentech, Inc.
BioNTech SE

Active, not recruiting

A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors

Melanoma | Head and Neck Cancer | Colorectal Cancer | Non-Small Cell Lung Cancer | Bladder Cancer | Triple Negative Breast Cancer | Renal Cancer | Other Solid Cancers

United States, Belgium, Sweden, Germany, Canada, Spain, United Kingdom, Netherlands
Altimmune, Inc.
Optimal Health Research

Completed

Immune Response Following Seasonal Influenza Vaccination

Influenza

United States
Immune-Onc Therapeutics
Regeneron Pharmaceuticals

Active, not recruiting

First-in-human Study of IO-108 as Single Agent and in Combination With a PD-1 Immune Check Point Inhibitor in Patients With Advanced Solid Tumors

Solid Tumor, Adult

United States
BioNTech Research & Development, Inc.
SciQuus Oncology

Terminated

Phase 1 Imaging Study of 89Zr-DFO-HuMab-5B1 With HuMab-5B1

Pancreatic Carcinoma | Tumors That Express CA19-9

United States
BioNTech US Inc.
Bristol-Myers Squibb

Completed

A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer

Melanoma | Carcinoma, Non-Small-Cell Lung | Lung Cancer | Urinary Bladder Cancer | Skin Cancer | Transitional Cell Carcinoma of the Bladder | Malignant Melanoma | Bladder Tumors

United States
Idorsia Pharmaceuticals Ltd.
Janssen Biotech, Inc.

Completed

A Research Study to Show the Effect of Aprocitentan in the Treatment of Difficult to Control (Resistant) High Blood Pressure (Hypertension) and Find Out More About Its Safety (PRECISION)

Resistant Hypertension

Spain, Israel, Czechia, United States, Canada, China, Hungary, Netherlands, Poland, United Kingdom, Germany, Australia, Belgium, Finland, France, Greece, Italy, Lithuania, Russian Federation, Ukraine
Idorsia Pharmaceuticals Ltd.
Janssen Biotech, Inc.

Completed

A Study to Evaluate How Aprocitentan is Safe and How it is Absorbed and Broken Down in the Body of Japanese and Caucasian Subjects

Healthy Subjects

United States
Southeastern Gynecologic Oncology
Ortho Biotech, Inc.

Completed

DOXIL for Consolidation Therapy in Ovarian Cancer.

Ovarian Neoplasm

United States

Clinical Trials Sponsored by Timmune Biotech Inc.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Luxembourg

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations